Abstract:Background: But so far there is no proven pharmacological treatment for Idiopathic pulmonary fibrosis (IPF). As trials investigating different agents with different mechanisms of actions are going on, encouraging results have led to the licensing of the first IPF-specific drug, Pirfenidone. Objective: To assess the proportion of IPF among interstitial lung disease patients and to assess their treatment response to Pirfenidone. Material and methods: All consecutive patients attending the outpatient department from 1st January 2012 to 30th June 2012 with a proven diagnosis of Interstitial lung Disease (ILD) were included in this longitudinal cohort study. Out of the total ILDs, patients with IPF were identified. The disease, its natural course, available treatment options and the risks and benefits of drugs were discussed with each IPF patient along with their family members. After obtaining their consent, we started 23 patients on a combination of Pirfenidone, N-acetyl cysteine (NAC) and proton pump inhibitors (PPI). Patients were followed up for 52 weeks. Pirfenidone was discontinued in one patient due to an adverse effect 1 month after onset of treatment. Anova test using SPSS software and independent T test was used to analyse the data. Results: During the study period 69 patients with ILD attended our OPD which included 24 IPF patients representing 34.8% and 23 of these patients received treatment with Pirfenidone, NAC and PPI. One patient discontinued Pirfenidone due to adverse effects. After 12 months, 8 patients had worsening of FVC ≥10%, the FVC of 7 patients remained stable, 8 patients could not repeat the tests and none of them had improvement. There was less than 15% decline in DLCO for 9 patients, 7 patients could not repeat the test and none improved. 8 patients had stable dyspnoea on exertion and 11 had worsening. Three patients died. Combining all the above parameters, only 4 patients had stable disease with the rest having no improvement. Conclusions: The present study does not show any significant beneficial effect for Pirfenidone. Only four patients remained stable which cannot be attributed to the effect of any particular management strategy.

Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis

Current and novel drug therapies for idiopathic pulmonary fibrosis

Perspectives of PDE Inhibitor on Treating Idiopathic Pulmonary Fibrosis

Emerging Opportunities to Treat Idiopathic Pulmonary Fibrosis: Design, Discovery, and Optimizations of Small-Molecule Drugs Targeting Fibrogenic Pathways.

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Updates in pharmacotherapy for idiopathic pulmonary fibrosis

The evolving pharmacotherapy of pulmonary fibrosis

Novel drug targets for idiopathic pulmonary fibrosis

Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials

An updated safety review of the drug treatments for idiopathic pulmonary fibrosis

Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis

[Idiopathic pulmonary fibrosis: recent diagnostic and therapeutic advances]

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study

Therapeutic Strategies for Idiopathic Pulmonary Fibrosis – Thriving Present and Promising Tomorrow

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies